Skandinaviska Enskilda Banken (SEB)
CTMX icon

Skandinaviska Enskilda Banken (SEB)’s CytomX Therapeutics CTMX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,400
Closed -$103K – 1045
2020
Q2 		$103K Buy
+12,400
New +$115K ﹤0.01% 960

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s CTMX Position: Q3 2020 in Review

Skandinaviska Enskilda Banken (SEB) sold out of CytomX Therapeutics (CTMX) in Q3 2020, closing a stake of 12,400 shares — an estimated $103K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CTMX in Q2 2020 and held it in 1 quarter. The position peaked at $103K in Q2 2020. 130 funds tracked by Wall St. Rank hold CTMX as of Q3 2020.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining CytomX Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 12,400 CytomX Therapeutics shares in Q3 2020, an estimated $103K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in CytomX Therapeutics in Q2 2020 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s CytomX Therapeutics position peaked at $103K in Q2 2020.
  • 130 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2020.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2020, filed 12 Nov 2020.